期刊
GLIA
卷 69, 期 11, 页码 2591-2604出版社
WILEY
DOI: 10.1002/glia.24060
关键词
cuprizone; DDAH1; EAE; oligodendrocyte differentiation; remyelination
资金
- Japan Society for the Promotion of Sciences [19H03554, 19K23789]
- Japan Agency for Medical Research and Development [21gm6210020h0002]
- Grants-in-Aid for Scientific Research [19H03554, 19K23789] Funding Source: KAKEN
Remyelination is a regenerative process that restores lost neurological function, partially dependent on oligodendrocyte differentiation. The study identified DDAH1 as a novel regulator of oligodendrocyte differentiation, with the potential to modulate remyelination in demyelinating diseases. Modulating DDAH1 activity could provide a new therapeutic option for demyelinating diseases.
Remyelination is a regenerative process that restores the lost neurological function and partially depends on oligodendrocyte differentiation. Differentiation of oligodendrocytes spontaneously occurs after demyelination, depending on the cell intrinsic mechanisms. By combining a loss-of-function genomic screen with a web-resource-based candidate gene identification approach, we identified that dimethylarginine dimethylaminohydrolase 1 (DDAH1) is a novel regulator of oligodendrocyte differentiation. Silencing DDAH1 in oligodendrocytes prevented the expression of myelin basic protein in mouse oligodendrocyte culture with the change in expression of genes annotated with oligodendrocyte development. DDAH1 inhibition attenuated spontaneous remyelination in a cuprizone-induced demyelinated mouse model. Conversely, increased DDAH1 expression enhanced remyelination capacity in experimental autoimmune encephalomyelitis. These results provide a novel therapeutic option for demyelinating diseases by modulating DDAH1 activity.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据